1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors.
Saved in:
| Title: | 1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. |
|---|---|
| Authors: | Tran, B.1 (AUTHOR), Millward, M.2 (AUTHOR), Lemech, C.3 (AUTHOR), Frentzas, S.4 (AUTHOR), Day, D.4 (AUTHOR), Latifi, A.5 (AUTHOR), Desai, J.1 (AUTHOR), Wabnitz, P.5 (AUTHOR), Kearney, P.5 (AUTHOR), Galkin, A.5 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS635-S635. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 173098978 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Tran%2C+B%2E%22">Tran, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Millward%2C+M%2E%22">Millward, M.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lemech%2C+C%2E%22">Lemech, C.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Frentzas%2C+S%2E%22">Frentzas, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Day%2C+D%2E%22">Day, D.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Latifi%2C+A%2E%22">Latifi, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Desai%2C+J%2E%22">Desai, J.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wabnitz%2C+P%2E%22">Wabnitz, P.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kearney%2C+P%2E%22">Kearney, P.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Galkin%2C+A%2E%22">Galkin, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2023 Supplement 2, Vol. 34, pS635-S635. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=173098978 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2023.09.2186 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S635 Titles: – TitleFull: 1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tran, B. – PersonEntity: Name: NameFull: Millward, M. – PersonEntity: Name: NameFull: Lemech, C. – PersonEntity: Name: NameFull: Frentzas, S. – PersonEntity: Name: NameFull: Day, D. – PersonEntity: Name: NameFull: Latifi, A. – PersonEntity: Name: NameFull: Desai, J. – PersonEntity: Name: NameFull: Wabnitz, P. – PersonEntity: Name: NameFull: Kearney, P. – PersonEntity: Name: NameFull: Galkin, A. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 10 Text: 2023 Supplement 2 Type: published Y: 2023 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 34 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
